Krystal Dietrich
Payments from drug & device makers
Across 174 payments — averaging $15.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Indivior Inc.$339
- Pfizer$239
- AbbVie$225
- Alkermes, Inc.$156
- Biohaven Pharmaceutical Holding Company Ltd.$154
- Boehringer Ingelheim$138
- plus $1K from 30 others
What the payments were for
- Food & beverage$2,722100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Indivior Inc. | 33 | $339 |
| Pfizer | 15 | $239 |
| AbbVie | 14 | $225 |
| Alkermes, Inc. | 7 | $156 |
| Biohaven Pharmaceutical Holding Company Ltd. | 14 | $154 |
| Boehringer Ingelheim | 7 | $138 |
| Pear Therapeutics (US), Inc. | 6 | $115 |
| Insulet Corporation | 3 | $103 |
| Merck | 6 | $101 |
| Novo Nordisk | 7 | $94 |
| Gilead | 4 | $78 |
| Novartis | 5 | $78 |
| Bayer | 4 | $77 |
| Lilly USA, LLC | 5 | $69 |
| Sanofi-aventis U.S. LLC | 4 | $64 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $59 |
| Zealand Pharma US, Inc. | 3 | $56 |
| Abbott | 3 | $55 |
| Braeburn Inc. | 3 | $54 |
| Biohaven Pharmaceuticals, Inc. | 3 | $52 |
| Xeris Pharmaceuticals, Inc. | 3 | $46 |
| Shield Therapeutics Inc | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Exact Sciences | 2 | $36 |
| Dexcom, Inc. | 2 | $33 |
| AstraZeneca | 2 | $31 |
| Daiichi Sankyo Inc. | 2 | $31 |
| Johnson & Johnson | 2 | $28 |
| Astellas Pharma US Inc | 1 | $24 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Corcept Therapeutics | 1 | $17 |
| Tandem Diabetes Care, Inc. | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
How this compares
$2,722 in reported general payments places this provider in the 85th percentile of 6,812 family providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 121 | $138,711 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 44 | $66,478 |
| OzempicSemaglutide | 53 | $60,608 |
| JardianceEmpagliflozin | 56 | $57,552 |
| Humalog Kwikpen U-200Insulin Lispro | 18 | $47,330 |
| TrulicityDulaglutide | 44 | $46,111 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 192 | $34,553 |
| EliquisApixaban | 26 | $25,192 |
| CaplytaLumateperone Tosylate | 12 | $20,453 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 22 | $18,046 |
| JanuviaSitagliptin Phosphate | 13 | $17,340 |
| XareltoRivaroxaban | 18 | $16,570 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 38 | $15,965 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 104 | $13,813 |
| Novolog FlexpenInsulin Aspart | 45 | $12,719 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $69 | $187,283185 claims |
| Novo NordiskOzempic | $94 | $60,60853 claims |
| Boehringer IngelheimJardiance | $138 | $57,55256 claims |
| PfizerEliquis | $239 | $25,19226 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $59 | $20,45312 claims |
| Indivior Inc.Suboxone | $339 | $18,04622 claims |
| MerckJanuvia | $101 | $17,34013 claims |
| Johnson & JohnsonXarelto | $28 | $16,57018 claims |
| AbbVieSynthroid | $225 | $3,54149 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,812 family providers in Ohio.
Other family in Lima
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.